top of page
  • Writer's pictureA2A Pharma

FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's Cancer

164 views0 comments

Recent Posts

See All

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of

Dr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE

bottom of page